Skip to main content
. Author manuscript; available in PMC: 2019 Jun 6.
Published in final edited form as: Sci Transl Med. 2018 Mar 7;10(431):eaam8460. doi: 10.1126/scitranslmed.aam8460

Figure 7: BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mice models.

Figure 7:

Colony formation assay of the indicated AML cell lines (a), 5 primary AML samples (b) and human CD34 cells (c) after BRD0705 treatment. Data represented as mean ± SEM of three replicates. (d) MLL-AF9 cells injected into secondary recipient mice after pretreatment with DMSO, BRD0705, BRD3731 or BRD0320 in a serially diluted manner. .Kaplan-Meier curves for the 250 000 cells dilution (n=5 per group). (e) Frequency of Leukemia Initiating Cells (LIC) calculated using ELDA software. (f) MLL-AF9 AML cells injected into secondary recipient mice before treatment with vehicle (black) or BRD0705 at 30 mg/kg (red). Kaplan-Meier curves for each group of mice (n=5 per group). (g) HL-60-Luc cells injected into recipient mice and treated with vehicle (black), BRD0705 at 15 mg/kg (red) or 30 mg/kg (blue). Bioluminescence was quantified. (h) Kaplan-Meier curves for each group of mice (n=5 per group). (i) MV4–11-Luc cells injected into recipient mice and treated with vehicle (black), BRD0705 (red), BRD3731 (blue) or BRD0320 (dashed blue). Bioluminescence was quantified. Data represented as mean ± SEM. P-value calculated on the latest time point. (j) Kaplan-Meier curves for each group of mice (n=10 per group). * p-value < 0.05 determined by log-rank (Mantel-Cox) test in comparison with vehicle.